Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study

Suarez Cuartin, Guillermo
Molina Molina, María

Publication date

October 2020

DOI

10.1183/20734735.0016-2019

Publisher

European Respiratory Society (ERS)

Language

English

Abstract

Kolb M, et al. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med 2018; 379: 1722–1731

Extracted data

Related items

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

Kolb, Martin
Richeldi, Luca
Behr, Jürgen
Maher, Toby M.
Tang, Wenbo
Stowasser, Susanne
Hallmann, Christoph
Bois, Roland M. du

January 2017

Rationale There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should ...

Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment

Cerri S.
Monari M.
Guerrieri A.
Donatelli P.
Bassi I.
Garuti M.
Luppi F.
Betti S.
Bandelli G.
Carpano M.
Bacchi Reggiani M. L.
Tonelli R.
Clini E.
Nava S.

January 2019

Background: Real-life data on the use of pirfenidone and nintedanib to treat patients with idiopathi...

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

Fletcher, SV
Jones, MG
Renzoni, EA
Parfrey, H
Hoyles, RK
Spinks, K
Kokosi, M
Kwok, A
Warburton, C
Titmuss, V
Thillai, M
Simler, N
Maher, TM
Brereton, CJ
Chua, F
Wells, AU
Richeldi, L
Spencer, LG

August 2018

In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the...

Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis

Kolb, Martin
Raghu, Ganesh
Wells, Athol U.
Behr, Jürgen
Richeldi, Luca
Schinzel, Birgit
Quaresma, Manuel
Stowasser, Susanne
Martinez
Fernando J
INSTAGE Investigator
Maria Pia Foschino Barbaro

January 2018

BACKGROUND: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup ...

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

Kreuter, M. (Michael)
Wuyts, W.A. (Wim A.)
Wijsenbeek-Lourens, M.S. (Marlies)
Bajwah, S. (Sabrina)
Maher, T.M. (Toby M.)
Stowasser, S. (Susanne)
Male, N. (Natalia)
Stansen, W. (Wibke)
Schoof, N. (Nils)
Orsatti, L. (Leticia)
Swigris, J. (Jeffrey)

January 2020

BACKGROUND: In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibro...

A real-life multicentric National study on nintedanib in severe idiopathic pulmonary fibrosis

Harari, Sergio
Caminati, Antonella
Poletti, Venerino
Confalonieri, Marco
Gasparini, Stefano
Lacedonia, Donato
Luppi, Fabrizio
Pesci, Alberto
Sebastiani, Alfredo
Spagnolo, Paolo
Vancheri, Carlo
Balestro, Elisabetta
Bonifazi, Martina
Cerri, Stefania
De Giacomi, Federica
Della Porta, Rossana
Foschino Barbaro Maria, Pia
Fui, Annalisa
Pasquinelli, Patrizio
Rosso, Roberta
Tomassetti, Sara
Specchia, Claudia
Paola, Rottoli

January 2018

BACKGROUND: Two therapeutic options are currently available for patients with mild-to-moderate idiop...

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Richeldi, Luca
Kolb, Martin
Jouneau, Stéphane
Wuyts, Wim A
Schinzel, Birgit
Stowasser, Susanne
Quaresma, Manuel
Raghu, Ganesh

January 2020

International audienceThe two 52-week INPULSIS trials investigated nintedanib versus placebo in pati...

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: Analyses of patient-reported outcomes from the INPULSIS® trials

Kreuter, Michael
Kreuter, Michael
Wuyts, Wim A.
Wijsenbeek, Marlies
Bajwah, Sabrina
Maher, Toby M.
Maher, Toby M.
Stowasser, Susanne
Male, Natalia
Stansen, Wibke
Schoof, Nils
Orsatti, Leticia
Swigris, Jeffrey

January 2020

Background: In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibro...

A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis

Harari, Sergio
Caminati, Antonella
Poletti, Venerino
Confalonieri, Marco
Gasparini, Stefano
Lacedonia, Donato
Luppi, Fabrizio
Pesci, Alberto
Sebastiani, Alfredo
Spagnolo, Paolo
Vancheri, Carlo
Balestro, Elisabetta
Bonifazi, Martina
Cerri, Stefania
De Giacomi, Federica
Della Porta, Rossana
Barbaro, Maria Pia Foschino
Fui, Annalisa
Pasquinelli, Patrizio
Rosso, Roberta
Tomassetti, Sara
Specchia, Claudia
Rottoli, Paola

January 2018

Background: Two therapeutic options are currently available for patients with mild-to-moderate idiop...

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis

Bonella, Francesco
Kreuter, Michael
Hagmeyer, Lars
Neurohr, Claus
Keller, Claus
Kohlhaeufl, Martin J.
Müller-Quernheim, Joachim
Milger, Katrin
Prasse, Antje

January 2016

Background: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis(IPF) and has b...

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

Abe M
Tsushima K
Sakayori M
Suzuki K
Ikari J
Terada J
Tatsumi K

October 2018

Mitsuhiro Abe,1 Kenji Tsushima,1,2 Masashi Sakayori,1 Kenichi Suzuki,1 Jun Ikari,1 Jiro Terada,1 Koi...

Real-life comparison of Pirfenidone and Nintedanib in patients with Idiopathic Pulmonary Fibrosis: a 24-month assessment.

Cerri Stefania
Monari Matteo
Guerrieri Aldo
DONATELLI, PIERLUIGI
Bassi Ilaria
Garuti&nbsp
Luppi Fabrizio
Betti Sara
Bandelli Giampiero
Carpano&nbsp
Bacchi-Reggiani Marialuisa
Tonelli Roberto
Clini Enrico
Nava Stefano.

January 2019

Background: Real-life data on the use of pirfenidone and nintedanib to treat patients with idiopathi...

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS (R) trials

Kreuter, Michael
Wuyts, Wim A
Wijsenbeek, Marlies
Bajwah, Sabrina
Maher, Toby M
Stowasser, Susanne
Male, Natalia
Stansen, Wibke
Schoof, Nils
Orsatti, Leticia
Swigris, Jeffrey

January 2020

BACKGROUND: In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibro...

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

Kolb, Martin
Richeldi, Luca
Behr, Jürgen
Maher, Toby M.
Tang, Wenbo
Stowasser, Susanne
Hallmann, Christoph
Bois, Roland M. du

January 2017

Rationale There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should ...

Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment

Cerri S.
Monari M.
Guerrieri A.
Donatelli P.
Bassi I.
Garuti M.
Luppi F.
Betti S.
Bandelli G.
Carpano M.
Bacchi Reggiani M. L.
Tonelli R.
Clini E.
Nava S.

January 2019

Background: Real-life data on the use of pirfenidone and nintedanib to treat patients with idiopathi...

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

Fletcher, SV
Jones, MG
Renzoni, EA
Parfrey, H
Hoyles, RK
Spinks, K
Kokosi, M
Kwok, A
Warburton, C
Titmuss, V
Thillai, M
Simler, N
Maher, TM
Brereton, CJ
Chua, F
Wells, AU
Richeldi, L
Spencer, LG

August 2018

In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the...

Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis

Kolb, Martin
Raghu, Ganesh
Wells, Athol U.
Behr, Jürgen
Richeldi, Luca
Schinzel, Birgit
Quaresma, Manuel
Stowasser, Susanne
Martinez
Fernando J
INSTAGE Investigator
Maria Pia Foschino Barbaro

January 2018

BACKGROUND: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup ...

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

Kreuter, M. (Michael)
Wuyts, W.A. (Wim A.)
Wijsenbeek-Lourens, M.S. (Marlies)
Bajwah, S. (Sabrina)
Maher, T.M. (Toby M.)
Stowasser, S. (Susanne)
Male, N. (Natalia)
Stansen, W. (Wibke)
Schoof, N. (Nils)
Orsatti, L. (Leticia)
Swigris, J. (Jeffrey)

January 2020

BACKGROUND: In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibro...

A real-life multicentric National study on nintedanib in severe idiopathic pulmonary fibrosis

Harari, Sergio
Caminati, Antonella
Poletti, Venerino
Confalonieri, Marco
Gasparini, Stefano
Lacedonia, Donato
Luppi, Fabrizio
Pesci, Alberto
Sebastiani, Alfredo
Spagnolo, Paolo
Vancheri, Carlo
Balestro, Elisabetta
Bonifazi, Martina
Cerri, Stefania
De Giacomi, Federica
Della Porta, Rossana
Foschino Barbaro Maria, Pia
Fui, Annalisa
Pasquinelli, Patrizio
Rosso, Roberta
Tomassetti, Sara
Specchia, Claudia
Paola, Rottoli

January 2018

BACKGROUND: Two therapeutic options are currently available for patients with mild-to-moderate idiop...

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Richeldi, Luca
Kolb, Martin
Jouneau, Stéphane
Wuyts, Wim A
Schinzel, Birgit
Stowasser, Susanne
Quaresma, Manuel
Raghu, Ganesh

January 2020

International audienceThe two 52-week INPULSIS trials investigated nintedanib versus placebo in pati...

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: Analyses of patient-reported outcomes from the INPULSIS® trials

Kreuter, Michael
Kreuter, Michael
Wuyts, Wim A.
Wijsenbeek, Marlies
Bajwah, Sabrina
Maher, Toby M.
Maher, Toby M.
Stowasser, Susanne
Male, Natalia
Stansen, Wibke
Schoof, Nils
Orsatti, Leticia
Swigris, Jeffrey

January 2020

Background: In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibro...

A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis

Harari, Sergio
Caminati, Antonella
Poletti, Venerino
Confalonieri, Marco
Gasparini, Stefano
Lacedonia, Donato
Luppi, Fabrizio
Pesci, Alberto
Sebastiani, Alfredo
Spagnolo, Paolo
Vancheri, Carlo
Balestro, Elisabetta
Bonifazi, Martina
Cerri, Stefania
De Giacomi, Federica
Della Porta, Rossana
Barbaro, Maria Pia Foschino
Fui, Annalisa
Pasquinelli, Patrizio
Rosso, Roberta
Tomassetti, Sara
Specchia, Claudia
Rottoli, Paola

January 2018

Background: Two therapeutic options are currently available for patients with mild-to-moderate idiop...

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis

Bonella, Francesco
Kreuter, Michael
Hagmeyer, Lars
Neurohr, Claus
Keller, Claus
Kohlhaeufl, Martin J.
Müller-Quernheim, Joachim
Milger, Katrin
Prasse, Antje

January 2016

Background: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis(IPF) and has b...

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

Abe M
Tsushima K
Sakayori M
Suzuki K
Ikari J
Terada J
Tatsumi K

October 2018

Mitsuhiro Abe,1 Kenji Tsushima,1,2 Masashi Sakayori,1 Kenichi Suzuki,1 Jun Ikari,1 Jiro Terada,1 Koi...

Real-life comparison of Pirfenidone and Nintedanib in patients with Idiopathic Pulmonary Fibrosis: a 24-month assessment.

Cerri Stefania
Monari Matteo
Guerrieri Aldo
DONATELLI, PIERLUIGI
Bassi Ilaria
Garuti&nbsp
Luppi Fabrizio
Betti Sara
Bandelli Giampiero
Carpano&nbsp
Bacchi-Reggiani Marialuisa
Tonelli Roberto
Clini Enrico
Nava Stefano.

January 2019

Background: Real-life data on the use of pirfenidone and nintedanib to treat patients with idiopathi...

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS (R) trials

Kreuter, Michael
Wuyts, Wim A
Wijsenbeek, Marlies
Bajwah, Sabrina
Maher, Toby M
Stowasser, Susanne
Male, Natalia
Stansen, Wibke
Schoof, Nils
Orsatti, Leticia
Swigris, Jeffrey

January 2020

BACKGROUND: In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibro...

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

Kolb, Martin
Richeldi, Luca
Behr, Jürgen
Maher, Toby M.
Tang, Wenbo
Stowasser, Susanne
Hallmann, Christoph
Bois, Roland M. du

January 2017

Rationale There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should ...

Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment

Cerri S.
Monari M.
Guerrieri A.
Donatelli P.
Bassi I.
Garuti M.
Luppi F.
Betti S.
Bandelli G.
Carpano M.
Bacchi Reggiani M. L.
Tonelli R.
Clini E.
Nava S.

January 2019

Background: Real-life data on the use of pirfenidone and nintedanib to treat patients with idiopathi...

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

Fletcher, SV
Jones, MG
Renzoni, EA
Parfrey, H
Hoyles, RK
Spinks, K
Kokosi, M
Kwok, A
Warburton, C
Titmuss, V
Thillai, M
Simler, N
Maher, TM
Brereton, CJ
Chua, F
Wells, AU
Richeldi, L
Spencer, LG

August 2018

In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the...